Investigational Therapy Tofersen Can Reduce Toxic SOD1 Protein Levels in Familial ALS Patients, Study Shows

Investigational Therapy Tofersen Can Reduce Toxic SOD1 Protein Levels in Familial ALS Patients, Study Shows

Biogen’s investigational therapy tofersen can significantly reduce toxic levels of SOD1 protein and may slow disability progression in people with familial amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, interim study results show. The positive data from a Phase 1/2 clinical trial support advancing the experimental compound into Phase 3 studies…

A Look at the ABCs of ALS During ALS Awareness Month

Awareness Breeds Compassion. Compassion Drives Enhanced Funding. Funding Generates Heightened Innovative Intervention Ideas. It all starts with awareness. May is ALS Awareness Month. It is not a coincidence that I chose three words beginning with the letter “I.” I believe that a single measure of awareness yields…

How My AFOs Helped Me Learn to Live with ALS

Sometimes we need a nudge to help us get over a mental funk and back into the swing of life. My nudge came from a pair of white ankle-foot orthoses (AFO) with whom I had been having a love-hate relationship. Love ’em or hate ’em, they did end up becoming an…